ProQR Announces Positive Interim Results from Phase 1/2 Clinical Trial of QR-110 in LCA10 Patients, and Plans to Start a Phase 2/3 Pivotal Trial

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/7/2026

1. HUVR:IN
2. ANET
3. NKE
4. PANW
5. CL
6. SNDK
7. TAP
8. DELL
9. ROIV
10. HUBS

Go back to ProQR Announces Positive Interim Results from Phase 1/2 Clinical Trial of QR-110 in LCA10 Patients, and Plans to Start a Phase 2/3 Pivotal Trial
(NASDAQ: PRQR) Delayed: 2.07 -0.02 (0.96%)
Previous Close $2.09    52 Week High $13.33 
Open $2.06    52 Week Low $3.48 
Day High $2.11    P/E N/A 
Day Low $2.06    EPS $0.00 
Volume 368,464